-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Financial App News, Colon Pharmaceutical (002422.SZ) announced that the company's holding subsidiary Collonbotai's antibody-conjugate drug (ADC) targeting human nourishing cell surface antigen 2 (TROP2) (Sac-TMT) (Cathailai®) in combination with MSD's anti-programmed cell death protein-1 (PD-1) monoclonal antibody pavolizumab (Krida®) first-line treatment of programmed cell death ligand-1 (PD-L1) is negative locally advanced or non-squamous nonsquamous Phase 3 clinical study of small cell lung cancer (NSCLC) (OptiTrop-Lung06), the primary end point of progression-free survival (PFS) was confirmed by the Independent Data Monitoring Committee (IDMC) in a predetermined mid-term analysis.

Zhitongcaijing·07/15/2026 04:09:03
Listen to the news
Zhitong Financial App News, Colon Pharmaceutical (002422.SZ) announced that the company's holding subsidiary Collonbotai's antibody-conjugate drug (ADC) targeting human nourishing cell surface antigen 2 (TROP2) (Sac-TMT) (Cathailai®) in combination with MSD's anti-programmed cell death protein-1 (PD-1) monoclonal antibody pavolizumab (Krida®) first-line treatment of programmed cell death ligand-1 (PD-L1) is negative locally advanced or non-squamous nonsquamous Phase 3 clinical study of small cell lung cancer (NSCLC) (OptiTrop-Lung06), the primary end point of progression-free survival (PFS) was confirmed by the Independent Data Monitoring Committee (IDMC) in a predetermined mid-term analysis.